1. Home
  2. KLXE vs MREO Comparison

KLXE vs MREO Comparison

Compare KLXE & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KLX Energy Services Holdings Inc.

KLXE

KLX Energy Services Holdings Inc.

HOLD

Current Price

$1.51

Market Cap

51.1M

Sector

Energy

ML Signal

HOLD

Logo Mereo BioPharma Group plc

MREO

Mereo BioPharma Group plc

HOLD

Current Price

$0.38

Market Cap

50.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KLXE
MREO
Founded
2018
2015
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Oilfield Services/Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
51.1M
50.3M
IPO Year
2018
2017

Fundamental Metrics

Financial Performance
Metric
KLXE
MREO
Price
$1.51
$0.38
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
★ $1.50
AVG Volume (30 Days)
962.0K
★ 1.7M
Earning Date
05-11-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 16.67
EPS
N/A
★ N/A
Revenue
★ $636,600,000.00
$500,000.00
Revenue This Year
$3.89
$5,184.20
Revenue Next Year
$4.95
$55.51
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.35
$0.20
52 Week High
$4.50
$2.37

Technical Indicators

Market Signals
Indicator
KLXE
MREO
Relative Strength Index (RSI) 43.86 69.14
Support Level $1.46 $0.35
Resistance Level $1.58 $0.42
Average True Range (ATR) 0.09 0.03
MACD 0.02 0.01
Stochastic Oscillator 49.25 84.21

Price Performance

Historical Comparison
KLXE
MREO

About KLXE KLX Energy Services Holdings Inc.

KLX Energy Services Holdings Inc is a growth-oriented provider of diversified oilfield services to onshore oil and natural gas exploration and production (E&P) companies operating in both conventional and unconventional plays in all of the active basins throughout the United States. It serves the companies engaged in the exploration and development of onshore conventional and unconventional oil and natural gas reserves. Its products and services offerings include surface facilities and equipment, pressure control services, wireline services, fishing services, and engineered products. The company's segments include Southwest; Rocky Mountains and Northeast/Mid-Con region. It derives maximum revenue from Southwest region.

About MREO Mereo BioPharma Group plc

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Share on Social Networks: